Showing 521-530 of 1457 results for "".
Currents: Updates and Innovations
https://practicaldermatology.com/programs/practical-dermatology/currents-updates-and-innovations/23832/The World Health Organization (WHO) will begin using “mpox” as a synonym for monkeypox. Both names will be used simultaneously for 1 year while “monkeypox” is phased out.Currents: Diversity In Dermatology
https://practicaldermatology.com/topics/skin-of-color/currents-diversity-in-dermatology/23760/Currents: Cosmetic Advancements In Focus
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/currents-cosmetic-advancements-in-focus/22071/Dermatologists Are Taking Action in Their Fight Against MOC
https://practicaldermatology.com/topics/practice-management/dermatologists-are-taking-action-in-their-fight-against-moc/20641/Maintenance of Certification (MOC) continues to be a thorny topic for some medical practitioners— and that may be stating the case mildly.Now What?
https://practicaldermatology.com/topics/psoriasis/now-what/20840/A look at what's now, what's next, and how dermatology practice continues to evolve with drugs, technologies, and opportunities.MOC Sparks Anger, Frustration in Physician Community
https://practicaldermatology.com/topics/practice-management/moc-sparks-anger-frustration-in-physician-community/20898/Anti-MOC advocates wonder why they cannot get a seat at the table to discuss changing the system.Reviving the Dream: Correcting Suboptimal Results from Injectable Treatments
https://practicaldermatology.com/topics/general-topics/PD0309_10-php/22864/Skill, patience and meticulous selection of products and injection techniques are pre-requisites for satisfactory correction of a poor outcome from treatment with dermal fillers and botulinum toxin.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20533/How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivRecognition of Chronic Alcoholism Key to Successful Treatment of Pellagra: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/recognition-of-chronic-alcoholism-key-to-successful-treatment-of-pellagra-a-case-report/20311/